AstraZeneca submits European application for drepression drug Seroquel XR

Published: 13-Jun-2008
Research & Development

AstraZeneca has made a European application for once-daily Seroquel XR extended-release tablets (quetiapine XR), for the treatment of major depressive disorder (MDD), including maintenance therapy in adult patients using the Mutual Recognition Procedure (MRP).


AstraZeneca has made a European application for once-daily Seroquel XR extended-release tablets (quetiapine XR), for the treatment of major depressive disorder (MDD), including maintenance therapy in adult patients using the Mutual Recognition Procedure (MRP).

This move follows a supplementary New Drug Application (sNDA) submission for Seroquel XR (quetiapine fumarate) in MDD in the US in February this year.

Each year, around 33 million people will suffer from MDD in Europe. Today, it is treated with generic or branded antidepressants, including selective serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs). Studies have shown at least one-third of patients fail to achieve a satisfactory response with current antidepressant therapy. Seroquel XR is the first atypical antipsychotic medicine to be submitted in Europe for approval for the treatment of MDD.

See more

You may also like

Manufacturing

Sapio Sciences introduces world’s first 3rd-generation ELN

Read more
Sapio ELaiN is an AI-powered lab notebook designed to act as a scientific collaborator

Trending Articles

  1. Douglas Pharmaceuticals sets new benchmark for capsule quality with CI Precision Partnership delivers compliance confidence, efficiency gains and reduced waste
  2. Servier acquires potential treatment for Fragile X syndrome KER-0193, a novel, orally bioavailable small molecule, was granted orphan drug and rare paediatric drug designation by the US FDA
  3. NICE recommends enfortumab vedotin with KEYTRUDA for adults in England/Wales with untreated metastatic urothelial cancer The results from the Phase III study EV-302/KN-A39 showed nearly a doubling of survival rates in patients compared with those who received platinum-based chemotherapy, which is the current standard of care in the UK
  4. Ryvu to support BioNTech’s clinical trials for cancer in Poland Ryvu will leverage its clinical network to streamline access to BioNTech’s investigational immunotherapies for Polish patients
  5. Intranasal GLP-1 medication from Orexo shows positive results in preclinical trial Orexo's AmorphOX technology had positive results when compared against oral and injectable formulations in the study

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Manufacturing

Sapio Sciences introduces world’s first 3rd-generation ELN

Sapio ELaiN is an AI-powered lab notebook designed to act as a scientific collaborator
Research & Development

Genoskin raises $8.7m in its first funding round to advance its ethical, human-based alternatives to animal testing

The financing will drive Genoskin’s next phase of growth, with a view to scaling up operations in both the US and France
Manufacturing

L.B. Bohle to showcase machines for OSD, food and nutraceuticals at PACK EXPO 2025

Company to present advanced blending, particle sizing and coating technologies at Las Vegas event
Drug Delivery

Tiziana receives grant for intranasal anti-CD3 monoclonal antibody therapy for spinal cord injury

The US Department of Defense awarded the biotechnology company a research grant to study the use of intranasal anti-CD3 therapy in traumatic spinal cord injury (SCI)
Regulatory

Novo Nordisk’s oral semaglutide scores EU approval for cardiovascular benefits

Rybelsus is now the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke
Manufacturing

Anton Paar launches next-generation rheometers for unmatched precision

New instrument series redefines possibilities in rheological testing and analysis
Drug Delivery

Rice University scientists create hydrogel platform for precision, long-lasting drug delivery

The researchers have developed a peptide hydrogel system that slows and extends drug release, improving treatment adherence and efficacy across therapies ranging from tuberculosis medication to insulin
Subscribe now